rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-206-218rsp-2220Research ArticleФОРУМ МОЛОДЫХ УЧЕНЫХYOUNG SCIENTISTS FORUMКлеточные и молекулярные биомаркеры и потенциальные терапевтические мишени при системной красной волчанкеCELLULAR AND MOLECULAR BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS IN SYSTEMIC LUPUS ERYTHEMATOSUSМеснянкинаА. А.MesnyankinaA. A.

лаборатория интенсивных методов терапии

аспирант, младший научный сотрудник (научный руководитель – профессор С.К. Соловьев)

34A, Kashirskoe Shosse, Moscow 115522 

a.a.mesnyankina@gmail.comФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian Federation201619072016542206218Copyright © Меснянкина А.А., 20162016Меснянкина А.А.Mesnyankina A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2220

Системная красная волчанка (СКВ) является одним из наиболее тяжелых и прогностически неблагоприятных системных заболеваний соединительной ткани, поражающим преимущественно женщин детородного возраста. Проводившиеся в последнее время научные исследования способствовали более глубокому пониманию ее патогенеза, выявлению и определению роли цитокинов, клеток и межклеточных связей, участвующих в развитии СКВ. Эти данные учитываются при разработке новых генно-инженерных биологических препаратов, действие которых направлено на ингибирование мишеней, участвующих в развитии заболевания. Эта информация позволяет также лучше понять механизм действия уже доказавших свою эффективность препаратов, таких как белимумаб и ритуксимаб. 

Systemic lupus erythematosus (SLE) is one of the most severe and prognostically poor systemic connective tissue diseases that affect mainly women of childbearing age. The recent researches have provided a deeper insight into its pathogenesis, the identification and definition of a role of cytokines, cells, and intercellular bonds involved in the development of SLE. These data are borne in mind when designing novel biological agents, the action of which is aimed at inhibiting the targets implicated in the development of the disease. This information also may provide better understanding the mechanism of action of drugs, such as belimumab and rituximab, which have already proven their efficacy. 

системная красная волчанкапатогенезлечениегенно-инженерные биологические препаратыsystemic lupus erythematosuspathogenesistreatmentbiological agentsReferencesНасонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008 [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National guidelines]. Mosсow: GEOTAR-Media; 2008].Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008 [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National guidelines]. Mosсow: GEOTAR-Media; 2008].Dai С, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014;0:87-96. doi: 10.1016/j.coi.2014.10.004 PMC4274270Dai С, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014;0:87-96. doi: 10.1016/j.coi.2014.10.004 PMC4274270Dorner T. Deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol. 2012;8(2):68-70. doi: 10.1038/nrrheum.2011.200Dorner T. Deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol. 2012;8(2):68-70. doi: 10.1038/nrrheum.2011.200Palanichamy A, Bauer JW, Yalavarthi S, et al. Neutrophil mediated IFN activation in the bone marrow alters B cell development in human and murine SLE. J Immunol. 2014;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30.Palanichamy A, Bauer JW, Yalavarthi S, et al. Neutrophil mediated IFN activation in the bone marrow alters B cell development in human and murine SLE. J Immunol. 2014;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30.Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27(high) plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1332- 42. doi: 10.1002/art.10949Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27(high) plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1332- 42. doi: 10.1002/art.10949Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44:1542-5. doi: 10.1093/rheumatology/kei080Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44:1542-5. doi: 10.1093/rheumatology/kei080Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580-9. doi: 10.1002/art.20430Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580-9. doi: 10.1002/art.20430Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076Kim JM, Park SH, Kim HY, et al. A plasmacytoid dendritic cells type I interferon axis is critically implicated in the pathogenesis of systemic lupus erythematosus. Int J Mol. 2015;16:14158-70. doi: 10.3390/ijms160614158Kim JM, Park SH, Kim HY, et al. A plasmacytoid dendritic cells type I interferon axis is critically implicated in the pathogenesis of systemic lupus erythematosus. Int J Mol. 2015;16:14158-70. doi: 10.3390/ijms160614158Podolska MJ, Biermann MH, Mauerö der C, et al. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015;8:161-71. doi: 10.2147/JIR.S70325. eCollection 2015. Review.Podolska MJ, Biermann MH, Mauerö der C, et al. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015;8:161-71. doi: 10.2147/JIR.S70325. eCollection 2015. Review.Ma K, Li J, FangY, et al. Roles of B cell-intrinsic TLR signals in systemic lupus erythematosus. Int J Mol Sci. 2015;16:13084-105. doi: 10.3390/ijms160613084. Review.Ma K, Li J, FangY, et al. Roles of B cell-intrinsic TLR signals in systemic lupus erythematosus. Int J Mol Sci. 2015;16:13084-105. doi: 10.3390/ijms160613084. Review.Rönnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 1991;30(4):537-40. doi: 10.3109/02841869109092414Rönnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 1991;30(4):537-40. doi: 10.3109/02841869109092414Squatrito D, Emmi G, Silvestri E, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014;5(2):33-45. doi: 10.1007/s13317-014-0058-y. eCollection 2014.Squatrito D, Emmi G, Silvestri E, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014;5(2):33-45. doi: 10.1007/s13317-014-0058-y. eCollection 2014.Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Review. Arthritis Res Ther. 2009;11:247. doi: 10.1186/ar2780. Epub 2009 Oct 14.Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Review. Arthritis Res Ther. 2009;11:247. doi: 10.1186/ar2780. Epub 2009 Oct 14.Александрова ЕН, Новиков АА, Соловьев СК и др. В- клетки при аутоиммунных ревматических заболеваниях. В кн.: Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА ПРЕСС; 2012. С. 8-45 [Alexandrova EN, Novikov AA, Soloviev SK, et al. B-cells in autoimmune rheumatic diseases. In: Nasonov EL, editor. Anti-B-kletochnaja terapija v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-PRESS; 2012. P. 8-45].Александрова ЕН, Новиков АА, Соловьев СК и др. В- клетки при аутоиммунных ревматических заболеваниях. В кн.: Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА ПРЕСС; 2012. С. 8-45 [Alexandrova EN, Novikov AA, Soloviev SK, et al. B-cells in autoimmune rheumatic diseases. In: Nasonov EL, editor. Anti-B-kletochnaja terapija v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-PRESS; 2012. P. 8-45].Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nature Immunology. 2004;5(60):645-50. doi: 10.1038/ni1076Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nature Immunology. 2004;5(60):645-50. doi: 10.1038/ni1076Wardemann H, Yurasov S, Schaefer A, et al Predominant autoan￾tibody production by early human B cell precursors. Science. 2003;301(5638):1374-7. doi: 10.1126/science.1086907Wardemann H, Yurasov S, Schaefer A, et al Predominant autoan￾tibody production by early human B cell precursors. Science. 2003;301(5638):1374-7. doi: 10.1126/science.1086907Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33. doi: 10.1056/NEJMoa021933Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33. doi: 10.1056/NEJMoa021933Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody–independ￾ent role for B cells in murine lupus. J Exp Med. 1999;189:1639-48. doi: 10.1084/jem.189.10.1639Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody–independ￾ent role for B cells in murine lupus. J Exp Med. 1999;189:1639-48. doi: 10.1084/jem.189.10.1639Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:1762-73. doi: 10.1002/art.23498Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:1762-73. doi: 10.1002/art.23498Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369. Epub 2014 Sep 8.Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369. Epub 2014 Sep 8.Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol. 2007;178:6624-33. doi: 10.4049/jimmunol.178.10.6624Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol. 2007;178:6624-33. doi: 10.4049/jimmunol.178.10.6624Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. doi: 10.1191/0961203304lu1023oaTackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. doi: 10.1191/0961203304lu1023oaAvery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112(2):286-97. doi: 10.1172/JCI18025Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112(2):286-97. doi: 10.1172/JCI18025Wei Yu Lin, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67(1):215-24. doi: 10.1002/art.38907Wei Yu Lin, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67(1):215-24. doi: 10.1002/art.38907Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029. doi: 10.1155/2014/419029. Epub 2014 Apr 23.Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029. doi: 10.1155/2014/419029. Epub 2014 Apr 23.Shin MS, Lee N, Kang I. Effector T cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol. 2011;23(5):444-8. doi: 10.1097/BOR.0b013e328349a255Shin MS, Lee N, Kang I. Effector T cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol. 2011;23(5):444-8. doi: 10.1097/BOR.0b013e328349a255Scalapino KJ, Tang Q, Bluestone JA, et al. Suppression of disease in New Zealand black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177(3):1451-9. doi: 10.4049/jimmunol.177.3.1451Scalapino KJ, Tang Q, Bluestone JA, et al. Suppression of disease in New Zealand black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177(3):1451-9. doi: 10.4049/jimmunol.177.3.1451Торгашина АВ, Быковская СЮ, Соловьев СК и др. Т-регуляторные клетки при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):50-9 [Torgashina AV, Biykovskaya SY, Soloviev SK, et al. T-regulatory cells in systemic lupus erythe￾matosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):50-9 (In Russ.)]. doi: 10.14412/1995-4484-2009-1313Торгашина АВ, Быковская СЮ, Соловьев СК и др. Т-регуляторные клетки при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):50-9 [Torgashina AV, Biykovskaya SY, Soloviev SK, et al. T-regulatory cells in systemic lupus erythe￾matosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):50-9 (In Russ.)]. doi: 10.14412/1995-4484-2009-1313Торгашина АВ. Взаимосвязь содержания Т-регуляторных клеток, уровня сывороточных аутоантител у больных системной красной волчанкой на фоне лечения ритуксимабом. Научно-практическая ревматология. 2009;47(2):3-9 [Torgashina AV. Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab. Nauchno￾Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):3-9 (In Russ.)]. doi: 10.14412/1995-4484- 2009-452Торгашина АВ. Взаимосвязь содержания Т-регуляторных клеток, уровня сывороточных аутоантител у больных системной красной волчанкой на фоне лечения ритуксимабом. Научно-практическая ревматология. 2009;47(2):3-9 [Torgashina AV. Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab. Nauchno￾Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):3-9 (In Russ.)]. doi: 10.14412/1995-4484- 2009-452Wen Z, Xu L, Xu W, et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing antidouble-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One. 2013;8(3):58161. doi: 10.1371/journal.pone.0058161. Epub 2013 Mar 5.Wen Z, Xu L, Xu W, et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing antidouble-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One. 2013;8(3):58161. doi: 10.1371/journal.pone.0058161. Epub 2013 Mar 5.Thompson JS, Bixler SA, Qian F. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-11. doi: 10.1126/science.1061965Thompson JS, Bixler SA, Qian F. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-11. doi: 10.1126/science.1061965Gras MP, Laabi Y, Linares-Cruz G, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995;7:1093-106. doi: 10.1093/intimm/7.7.1093Gras MP, Laabi Y, Linares-Cruz G, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995;7:1093-106. doi: 10.1093/intimm/7.7.1093Von Bulow GU, Bram RJ. NF-AT activation induced by a CAMLinteracting member of the tumor necrosis factor receptor superfam￾ily. Science. 1997;278:138-41. doi: 10.1126/science.278.5335.138Von Bulow GU, Bram RJ. NF-AT activation induced by a CAMLinteracting member of the tumor necrosis factor receptor superfam￾ily. Science. 1997;278:138-41. doi: 10.1126/science.278.5335.138Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-52. doi: 10.1016/S0960-9822(01)00481-XYan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-52. doi: 10.1016/S0960-9822(01)00481-XMackay F, Figgett WA, Saulep D, et al. B-cell stage and contextdependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev. 2010;237:205-25. doi: 10.1111/j.1600-065X.2010.00944.xMackay F, Figgett WA, Saulep D, et al. B-cell stage and contextdependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev. 2010;237:205-25. doi: 10.1111/j.1600-065X.2010.00944.xTreml JF, Hao Y, Stadanlick JE, et al. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.Treml JF, Hao Y, Stadanlick JE, et al. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.Супоницкая ЕВ, Александрова ЕН, Насонов ЕЛ. Клиническое значение BAFF/BLyS и APRIL при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2014;52(5):545-52 [Suponitskya EV, Aleksandrova EN, Nasonov EL. Clinical significance of BAFF/BLyS and APRIL in systemic lupus erythematosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):545-52 (In Russ.)]. doi: 10.14412/1995-4484-2014-545-552Супоницкая ЕВ, Александрова ЕН, Насонов ЕЛ. Клиническое значение BAFF/BLyS и APRIL при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2014;52(5):545-52 [Suponitskya EV, Aleksandrova EN, Nasonov EL. Clinical significance of BAFF/BLyS and APRIL in systemic lupus erythematosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):545-52 (In Russ.)]. doi: 10.14412/1995-4484-2014-545-552Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697-710. doi: 10.1084/jem.190.11.1697Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697-710. doi: 10.1084/jem.190.11.1697Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA. 2000;97:3370-5. doi: 10.1073/pnas.97.7.3370Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA. 2000;97:3370-5. doi: 10.1073/pnas.97.7.3370Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-9. doi: 10.1038/35010115Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-9. doi: 10.1038/35010115Elbirt D, Asher I, Mahlab-Guri K, et al. BLyS levels in sera of patients with systemic lupus erythematosus: Clinical and Serological Correlation. IMAJ. 2014;16:491-6.Elbirt D, Asher I, Mahlab-Guri K, et al. BLyS levels in sera of patients with systemic lupus erythematosus: Clinical and Serological Correlation. IMAJ. 2014;16:491-6.Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475-86. doi: 10.1002/art.11354Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475-86. doi: 10.1002/art.11354Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-9. doi: 10.1002/art.23678Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-9. doi: 10.1002/art.23678Davidson A. The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2012;14(4): 295–302. doi: 10.1007/s11926-012-0258-2Davidson A. The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2012;14(4): 295–302. doi: 10.1007/s11926-012-0258-2Scapini P, Hu Y, Chu CL, et al. Myeloid cells, BAFF, and IFN- {gamma} establish an inflammatory loop that exacerbates autoim￾munity in Lyn-deficient mice. J Exp Med. 2010;207:1757-73. doi: 10.1084/jem.20100086. Epub 2010 Jul 12.Scapini P, Hu Y, Chu CL, et al. Myeloid cells, BAFF, and IFN- {gamma} establish an inflammatory loop that exacerbates autoim￾munity in Lyn-deficient mice. J Exp Med. 2010;207:1757-73. doi: 10.1084/jem.20100086. Epub 2010 Jul 12.Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol. 2008;180:7394-403. doi: 10.4049/jimmunol.180.11.7394Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol. 2008;180:7394-403. doi: 10.4049/jimmunol.180.11.7394Jacob CO, Guo S, Jacob N. Dispensability of APRIL to the devel￾opment of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012;64(5):1610-9. doi: 10.1002/art.33458Jacob CO, Guo S, Jacob N. Dispensability of APRIL to the devel￾opment of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012;64(5):1610-9. doi: 10.1002/art.33458Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012;14(6):R252. doi: 10.1186/ar4095Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012;14(6):R252. doi: 10.1186/ar4095Morel J, Hahne M. To target or not to target APRIL in systemic lupus erythematosus: that is the question! Arthritis Res Ther. 2013;15(1):107. doi: 10.1186/ar4160Morel J, Hahne M. To target or not to target APRIL in systemic lupus erythematosus: that is the question! Arthritis Res Ther. 2013;15(1):107. doi: 10.1186/ar4160Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int. 2014;34(9):1217-23. doi: 10.1007/s00296-014-3020-4. Epub 2014 Apr 21.Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int. 2014;34(9):1217-23. doi: 10.1007/s00296-014-3020-4. Epub 2014 Apr 21.Yap DY, Lai KN. The role of cytokines in the pathogenesis of sys￾temic lupus erythematosus – from bench to bedside. Nephrology. 2013;18(4):243-55. doi: 10.1111/nep.12047Yap DY, Lai KN. The role of cytokines in the pathogenesis of sys￾temic lupus erythematosus – from bench to bedside. Nephrology. 2013;18(4):243-55. doi: 10.1111/nep.12047Iwano M, Dohi K, Hirata E. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol.1993;40:16-21.Iwano M, Dohi K, Hirata E. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol.1993;40:16-21.Tsai CY, Wu TH, Yu CL. Increased excretions of beta2- microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephri￾tis. Nephron. 2000;85:207-14. doi: 10.1159/000045663Tsai CY, Wu TH, Yu CL. Increased excretions of beta2- microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephri￾tis. Nephron. 2000;85:207-14. doi: 10.1159/000045663Gröndal G, Gunnarsson I, Rönnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565-70.Gröndal G, Gunnarsson I, Rönnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565-70.Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):138-50. doi: 10.1007/s12016-010-8197-zReyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):138-50. doi: 10.1007/s12016-010-8197-zRyffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol. 1994;144:927-37.Ryffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol. 1994;144:927-37.Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37:60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37:60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998;112(3):397-402. doi: 10.1046/j.1365-2249.1998.00612.xMihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998;112(3):397-402. doi: 10.1046/j.1365-2249.1998.00612.xFinck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994;94:585-91. doi: 10.1172/JCI117373Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994;94:585-91. doi: 10.1172/JCI117373Hirohata S, Kanai Y, Mitsuo A, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319-23. doi: 10.1007/s10067-009-1226-8. Epub 2009 Jul 12.Hirohata S, Kanai Y, Mitsuo A, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319-23. doi: 10.1007/s10067-009-1226-8. Epub 2009 Jul 12.Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004;6:551-6. doi: 10.1186/ar1228. Epub: 2004 Sep 23.Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004;6:551-6. doi: 10.1186/ar1228. Epub: 2004 Sep 23.Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56(4):1242-50. doi: 10.1002/art.22451Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56(4):1242-50. doi: 10.1002/art.22451Eilertsen GO, Nikolaisen C, Becker-Merok A, et al. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 2011;20(6):607-13. doi: 10.1177/0961203310392432. Epub 2011 Mar 21.Eilertsen GO, Nikolaisen C, Becker-Merok A, et al. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 2011;20(6):607-13. doi: 10.1177/0961203310392432. Epub 2011 Mar 21.Vasoo S, Hughes GRV. Perspectives on the changing face of lupus mortality. Autoimmun Rev. 2004;3:415-7. doi: 10.1016/j.autrev.2004.06.005Vasoo S, Hughes GRV. Perspectives on the changing face of lupus mortality. Autoimmun Rev. 2004;3:415-7. doi: 10.1016/j.autrev.2004.06.005Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corti￾costeroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-82. doi: 10.1002/art.1780390906Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corti￾costeroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-82. doi: 10.1002/art.1780390906Anolik JH, Barnard J, Cappione A. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580-90. doi: 10.1002/art.20592Anolik JH, Barnard J, Cappione A. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580-90. doi: 10.1002/art.20592Левицки А, Линдео С, ван Волленховен РФ. Ритуксимаб в терапии системной красной волчанки. Научно-практическая ревматология. 2013;51(3):223-39 [Levitsky A, Linder S, van Vollenhoven RF. Rituximab in the management of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):223-39 (In Russ.)].Левицки А, Линдео С, ван Волленховен РФ. Ритуксимаб в терапии системной красной волчанки. Научно-практическая ревматология. 2013;51(3):223-39 [Levitsky A, Linder S, van Vollenhoven RF. Rituximab in the management of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):223-39 (In Russ.)].Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В- клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.)]. doi: 10.14412/1995- 4484-2014-495-506Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В- клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.)]. doi: 10.14412/1995- 4484-2014-495-506Асеева ЕА, Соловьев СК, Насонов ЕЛ. Генно-инженерные биологические препараты в терапии системной красной волчанки. Современная ревматология. 2013;7(3):33-40 [Aseeva EA, Solovyev SK, Nasonov EL. Genetically engineered biological agents in therapy for systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(3):33-40 (In Russ.)]. doi: 10.14412/1996- 7012-2013-11Асеева ЕА, Соловьев СК, Насонов ЕЛ. Генно-инженерные биологические препараты в терапии системной красной волчанки. Современная ревматология. 2013;7(3):33-40 [Aseeva EA, Solovyev SK, Nasonov EL. Genetically engineered biological agents in therapy for systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(3):33-40 (In Russ.)]. doi: 10.14412/1996- 7012-2013-11Paran D, Naparstek Y. Is B cell-targeted therapy effective in systemic lupus erythematosus? Isr Med Assoc J. 2015;17(2):98-103. Review.Paran D, Naparstek Y. Is B cell-targeted therapy effective in systemic lupus erythematosus? Isr Med Assoc J. 2015;17(2):98-103. Review.Насонов ЕЛ, Соловьев СК. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-21 [Nasonov EL, Solovyev SK. Prospects for pharmacotherapy of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):311-21 (In Russ.)]. doi: 10.14412/1995- 4484-2014-311-321Насонов ЕЛ, Соловьев СК. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-21 [Nasonov EL, Solovyev SK. Prospects for pharmacotherapy of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):311-21 (In Russ.)]. doi: 10.14412/1995- 4484-2014-311-321Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237:264-83. doi: 10.1111/j.1600-065X.2010.00945.xTownsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237:264-83. doi: 10.1111/j.1600-065X.2010.00945.xRoll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377-86. doi: 10.1002/art.22019Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377-86. doi: 10.1002/art.22019Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038-47. doi: 10.1002/art.30466Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038-47. doi: 10.1002/art.30466Tew GW, Rabbee N, Wolslegel K. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752. Epub: 2009 Nov 27.Tew GW, Rabbee N, Wolslegel K. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752. Epub: 2009 Nov 27.Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724-31. doi: 10.1136/ard.2007.083162. Epub: 2008 Feb 4.Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724-31. doi: 10.1136/ard.2007.083162. Epub: 2008 Feb 4.Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar1954. Epub: 2006 May 5Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar1954. Epub: 2006 May 5Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus – safety, preliminary efficacy, and impact on circulating plasma cells. Arthritis Rheum. 2010;62(2):542-52. doi: 10.1002/art.27221Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus – safety, preliminary efficacy, and impact on circulating plasma cells. Arthritis Rheum. 2010;62(2):542-52. doi: 10.1002/art.27221Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin- 6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-28. doi: 10.1136/annrheumdis-2012-201310. Epub 2012 Aug 2.Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin- 6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-28. doi: 10.1136/annrheumdis-2012-201310. Epub 2012 Aug 2.Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62-74. doi: 10.1016/j.clim.2006.08.016. Epub 2006 Oct 13.Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62-74. doi: 10.1016/j.clim.2006.08.016. Epub 2006 Oct 13.Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044-56. doi: 10.1002/art.22810Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044-56. doi: 10.1002/art.22810Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-10. doi: 10.1002/art.27189Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-10. doi: 10.1002/art.27189Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-65. doi: 10.1002/art.11299Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-65. doi: 10.1002/art.11299Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamics and toxicologic effects. Toxicol Sci. 2006;91:586-99. doi: 10.1093/toxsci/kfj148. Epub: 2006 Mar 3.Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamics and toxicologic effects. Toxicol Sci. 2006;91:586-99. doi: 10.1093/toxsci/kfj148. Epub: 2006 Mar 3.Насонов ЕЛ, Решетняк ТМ, Денисов ЛН и др. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;54(5):13-9 [Nasonov EL, Reshetnjak TM, Denisov LN, et al. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;54(5):13-9 (In Russ.)].Насонов ЕЛ, Решетняк ТМ, Денисов ЛН и др. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;54(5):13-9 [Nasonov EL, Reshetnjak TM, Denisov LN, et al. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;54(5):13-9 (In Russ.)].Zouali M, Uy EA. Belimumab therapy in systemic lupus erythematosus. BioDrugs. 2013;27:225-35. doi: 10.1007/s40259-013- 0031-8Zouali M, Uy EA. Belimumab therapy in systemic lupus erythematosus. BioDrugs. 2013;27:225-35. doi: 10.1007/s40259-013- 0031-8Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol. 2011;187:6571-80. doi: 10.4049/jimmunol.1101784. Epub 2011 Nov 18.Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol. 2011;187:6571-80. doi: 10.4049/jimmunol.1101784. Epub 2011 Nov 18.Nikbakht N, Migone TS, Ward CP, et al. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J Immunol. 2011; 187:37-46. doi: 10.4049/jimmunol.1003924. Epub 2011 Jun 1.Nikbakht N, Migone TS, Ward CP, et al. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J Immunol. 2011; 187:37-46. doi: 10.4049/jimmunol.1003924. Epub 2011 Jun 1.Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515Vallerskog T, Heimbü rger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:167. doi: 10.1186/ar2076Vallerskog T, Heimbü rger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:167. doi: 10.1186/ar2076Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700-3. doi: 10.1136/ard.2006.060772. Epub 2006 Oct 13Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700-3. doi: 10.1136/ard.2006.060772. Epub 2006 Oct 13Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012. doi: 10.1136/bcr-2012- 007834Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012. doi: 10.1136/bcr-2012- 007834Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75(8):835-46. doi: 10.1007/s40265-015-0394-xMathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75(8):835-46. doi: 10.1007/s40265-015-0394-x

The authors declare that there are no conflicts of interest present.